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To investigate whether partner bereavement is associated with adverse cardiovascular and
kidney-related events in people with reduced kidney function.
Design
Two parallel matched cohort studies using linked routinely collected health data.
Setting
England (general practices and hospitals using linked Clinical Practice Research Datalink,
Hospital Episode Statistics, and Office of National Statistics) and Denmark (hospitals and
community pharmacies using the Danish National Patient, Prescription and Education Reg-
istries and the Civil Registration System).
Participants
Bereaved people with reduced kidney function (estimated glomerular filtration rate (eGFR)
<60mL/min/1.73m2 (England) or hospital-coded chronic kidney disease (Denmark)) and
non-bereaved people with reduced kidney function similarly defined, matched on age, sex,
general practice (England), and county of residence (Denmark) and followed-up from the
bereavement date of the exposed person.
Main outcome measures
Cardiovascular disease (CVD) or acute kidney injury (AKI) hospitalization, or death.
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Results
In people with reduced kidney function, we identified 19,820 (England) and 5,408 (Denmark)
bereaved individuals and matched them with 134,828 (England) and 35,741 (Denmark)
non-bereaved individuals. Among the bereaved, the rates of hospitalizations (per 1000 per-
son-years) with CVD were 31.7 (95%-CI: 30.5–32.9) in England and 78.8 (95%-CI: 74.9–
82.9) in Denmark; the rates of hospitalizations with AKI were 13.2 (95%-CI: 12.5–14.0) in
England and 11.2 (95%-CI: 9.9–12.7) in Denmark; and the rates of death were 70.2 (95%-
CI: 68.5–72.0) in England and 126.4 (95%-CI: 121.8–131.1) in Denmark. After adjusting for
confounders, we found increased rates of CVD (England, HR 1.06 [95%-CI: 1.01–1.12];
Denmark, HR 1.10 [95%-CI: 1.04–1.17]), of AKI (England, HR 1.20 [95%-CI: 1.10–1.31];
Denmark HR 1.36 [95%-CI: 1.17–1.58]), and of death (England, HR 1.10 [95%-CI: 1.05–
1.14]; Denmark HR 1.20 [95%-CI: 1.15–1.25]) in bereaved compared with non-bereaved
people.
Conclusions
Partner bereavement is associated with an increased rate of CVD and AKI hospitalization,
and death in people with reduced kidney function. Additional supportive care for this at-risk
population may help prevent serious adverse events.
Background
Reduced kidney function is common, affecting at least 5–8% of people of all ages in England
and Denmark [1–3]. The prevalence of chronic kidney disease (CKD), the formal diagnosis of
reduced kidney function, is at least 30% in people over age 75 [4]. CKD is a progressive and
complex disease that is associated with increased risk of acute kidney injury (AKI) [5], stroke
[6,7], myocardial infarction [8], and heart failure [9,10], It is unknown to what extent an acute
stressor, such as partner bereavement, impacts adverse outcomes in this vulnerable
population.
Partner bereavement is one of the most stressful acute life events according to the Social
Readjustment Scale [11]. Previous observational studies in the general population have shown
that it is associated with short-term increased risk of cardiovascular disease (CVD) and death
[12–22]. Possible mechanisms for these associations could be explained by stress manifesting
through physiological or behavioural changes in people who are bereaved. For example, previ-
ous studies observed immunological changes following partner bereavement, particularly in
older adults [23,24]. In addition, decreased adherence to treatment recommendations due to
the loss of a caregiver or disruption to routine, as well as unhealthy lifestyle changes (e.g.
increased intake of unhealthy foods or alcohol) following partner bereavement could explain
these associations.
The impact of partner bereavement on kidney-related outcomes and in people with
reduced kidney function is not well described. One study observed considerable declines in
the kidney function of caregivers in the three months after their partner’s move into a nursing
home [25]. In addition, people living with kidney disease have been described as needing more
bereavement counselling than those living with other diseases [26], and that current bereave-
ment support for people with end-stage renal disease (ESRD) was generally perceived as poor
[27]. Better evidence quantifying the impact of partner bereavement on adverse outcomes in
PLOS ONE Adverse outcomes after partner bereavement in people with reduced kidney function
PLOS ONE | https://doi.org/10.1371/journal.pone.0257255 September 23, 2021 2 / 15
distribute or make patient data directly available to
other parties. Data access may be applied for at the
Statistics Denmark. The authors do not have
special access privileges to these data. Approvals
to use the English data sources for the current
study also do not allow us to distribute or make
patient data directly available to other parties. Data
access may be applied for through the Clinical
Practice Research Datalink (CPRD), https://www.
cprd.com/. Codelists used to identify outcomes in
both England and Denmark, and covariates in
England are published on LSHTM data compass
(https://doi.org/10.17037/DATA.00002263).
Codelists to identify covariates in Denmark are
listed in S6–S7 Methods. We cannot disseminate
study results directly to study participants, since
we used de-identified data in both England and
Denmark.
Funding: The Danish analyses were partly funded
by the Beckett Foundation. SML is funded by a
Wellcome Senior Clinical Fellowship in Science
(205039/Z/16/Z). For the purpose of Open Access,
the author has applied a CC BY public copyright
license to any Author Accepted Manuscript (AAM)
version arising from this submission. The funders
had no role in study design, data collection and
analysis, decision to publish, or preparation of the
manuscript.
Competing interests: I have read the journal’s
policy and the authors of this manuscript have the
following competing interests: All authors have
completed an ICJME disclosure form. AH, PB, AK,
AYSW, SAJS declare no competing interests,
including relevant financial interests, activities,
relationships or affiliations. SVV was supported by
The Beckett Foundation by a grant administered by
Aarhus University which supported this
manuscript. DN is the UK Renal Association
Director of Informatics Research, a member of the
steering group for two GlaxoSmithKline funded
studies of kidney function in Sub-Saharan Africa
and receives funding from the Health Foundation
and the Medical Research Council unrelated to the
work in this paper. SVV, CFC, and AK are members
of Aarhus University Department of Clinical
Epidemiology and are involved in studies with
funding from various companies as research
grants to (and administered by) Aarhus University.
SML is funded by a Wellcome Senior Clinical
Fellowship in Science (205039/Z/16/Z) and was
funded by the European Academy of Dermatology
and Venerology (PPRC-2016-019) for previous
bereavement-related research. SL has received
consulting fees from STAART-AKI Study Group
(reviewing patient information sheets) and the
NIHR (lay reviewer), has received payments for
people living with reduced kidney function would inform the design of improved supportive
care for this vulnerable population. This topic is particularly relevant in the context of the
coronavirus disease (COVID)-19 pandemic, which has likely increased the number of people
experiencing partner bereavement.
We aimed to determine whether bereavement in people with reduced kidney function is
associated with an increased risk of CVD, AKI, or death. We used routinely collected health
data from the UK (1998–2018) and Denmark (1997–2016) to estimate the rate of CVD, AKI,
and death in people with reduced kidney function comparing bereaved people with non-
bereaved people.
Methods
Study design and setting
We conducted two parallel matched cohort studies using routinely collected health data from
England and Denmark.
Data sources
England. We used the Clinical Practice Research Datalink (CPRD) Gold primary care
data linked to Hospital Episode Statistics (HES) secondary care data, the Index of Multiple
Deprivation (IMD), and the Office for National Statistics (ONS) mortality data. We restricted
the United Kingdom (UK) primary care cohort to England only since HES is only available in
England. CPRD Gold data are shown to be largely representative of the UK population in
terms of age, sex, and ethnicity, and include approximately 7% of the UK population [28]. Fur-
ther details on these datasets are provided in S1 Methods.
Denmark. We used national registries linked at the individual level using a unique per-
sonal identifier assigned to all Danish residents. We obtained age, sex, civil, and vital status on
every Dane from the Danish Civil Registration System [29]. We collected detailed data on
inpatient, outpatient, and emergency visits from the Danish National Patient Registry; [30]
prescriptions filled at outpatient pharmacies from the Danish National Prescription Registry;
[31] and educational attainment from the Danish Education Registers [32]. Further details on
these registries are provided in S2 Methods.
Study population
England. We identified partners using an algorithm previously developed using CPRD
data [33] (further details are provided in S3 Methods). We identified people who experienced
the death of their partner between 1 January 1998 to 31 July 2018 in our bereaved group. We
restricted to those registered for�1 year at a General Practice (GP) contributing research qual-
ity data to the CPRD. Furthermore, we restricted to bereaved individuals with a serum creati-
nine (SCr) laboratory test corresponding to an eGFR<60mL/min/1.73m2 recorded by the GP
within five years prior to the partner death date. We calculated estimated glomerular filtration
rate (eGFR) using the Chronic Kidney Disease Epidemiology Collaboration equation [34]
(without ethnicity since ethnicity data are incompletely recorded in CPRD-HES). People with
no SCr measurement were excluded, as we presumed they had normal kidney function. We
defined the partner death date as the index date used to match a comparison cohort.
Among the couples identified by the partner algorithm, we sampled an unexposed (com-
parison) cohort of people with a living partner matched on age (within +/- 1 year), sex, and GP
with replacement. We excluded those who did not have an eGFR measure<60mL/min/
1.73m2 within 5 years prior to the index date of the exposed (bereaved) person to whom they
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were matched. We kept a maximum of 10 matched unexposed persons for each exposed
person.
Denmark. In Denmark, the study was nested in an established population of people who
lost a partner during 1997–2016 (bereaved) and their non-bereaved comparisons from the
general population, matched 1:10 by age, sex and county of residence [35]. In this population,
we identified every bereaved person with hospital-recorded CKD (inpatient or outpatient)
before the bereavement date, and matched them 1:10 with replacement to non-bereaved peo-
ple of the same age (+/- 5 years), sex and county of residence with hospital-recorded CKD
before the index date. The bereaved partners were identified using an algorithm developed by
Statistics Denmark [33] (further details are provided in S4 Methods).
In both England and Denmark, unexposed individuals were censored and moved to the
exposed group if they experienced partner bereavement during follow-up.
Outcomes
Our primary outcomes were first hospitalizations during follow-up for CVD (composite of
heart failure, myocardial infarction, and stroke) or AKI, and death. Secondary outcomes
included first hospitalizations for heart failure, myocardial infarction, and stroke individually.
We identified first CVD and AKI hospitalizations using ICD-10 codes in the first or second
diagnostic position of the inpatient admission’s first episode (England) or as a primary or sec-
ondary diagnosis in inpatients or outpatients (Denmark). The admission date was used to
define the date of the outcome event. We identified deaths using the death date in ONS, or the
death date in CPRD if death date in ONS was missing (England) and the Civil Registration
System (Denmark).
We followed each participant from the index date until the earliest of the following: date of
outcome, death, date of last data collection from the practice (England), transfer out of the
general practice for either member of the couple (England), emigration of either member of
the couple (Denmark) or the end of study period (31 July 2018 in England, 31 December 2016
in Denmark). We analysed each outcome independently.
Covariates
We identified potential confounders using hospitalization data, GP data (England only), and
civil registration data (Denmark only). Potential confounders included relevant comorbidities
and demographic characteristics (age, sex, and socioeconomic status (SES)). In England, we
also identified body-mass index (BMI), alcohol intake, and smoking status as potential con-
founders (defined as described previously [36] and in S5 Methods). These lifestyle data were
not available in the Danish data. In both countries, we obtained information from hospital and
GP (England only) data anytime before the index date on previously diagnosed AKI, cerebro-
vascular disease, chronic obstructive pulmonary disease, diabetes, hypertension, myocardial
infarction, other ischaemic heart disease, peripheral artery disease, connective tissue diseases,
dementia, peptic ulcer, non-haematological malignancies, haematological malignancies, liver
disease, and prevalent heart failure. In Denmark, diabetes was defined as either a hospital diag-
nosis or a filled prescription for an antidiabetic drug. In England, we used the most recent
eGFR recorded in primary care to categorise baseline CKD stage according to cut-points from
the Kidney Disease Improving Global Outcomes guidelines (data unavailable in Denmark)
[37]. These categories were CKD stage 3a (eGFR 45-59mL/min/1.73m2), CKD stage 3b (eGFR
30-44mL/min/1.73m2), and CKD stages 4–5 (eGFR 0-30mL/min/1.73m2). In Denmark, dura-
tion of CKD was defined as time since first CKD diagnosis at index date. eGFR data were not
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available in the data sources we used in Denmark. As a proxy for SES, we used IMD quintiles
(England) or highest educational attainment (Denmark).
Statistical analysis
We summarised baseline characteristics and absolute rates per 1,000 person-years (PY) for
each outcome by exposure status (bereaved or non-bereaved) in both countries. We then used
Cox proportional hazards models to calculate unadjusted hazard ratios (HR) with 95% confi-
dence intervals (CI) for each outcome stratified by matched sets to account for the matching
factors. In an adjusted model, we then added comorbidities, history of AKI, SES, and lifestyle
factors (England only) as covariables. We used a complete case approach since the missing
data (on lifestyle variables in England and educational attainment in Denmark) are unlikely to
be missing at random with respect to the outcome and therefore multiple imputation would
be invalid [38]. We stratified results for primary outcomes by age group (<64 years, 65–74
years, and 75+ years), sex, prevalent CVD (for the CVD outcome only), and CKD stage
(England only) and presented the stratified HR and 95% CI for each category. We specified all
analyses a priori. We assessed proportionality by visual inspection of log-log plots.
We conducted two sensitivity analyses in the English cohort to assess the robustness of our
results. First, we shortened the study period to 1 January 2010–31 July 2018 since AKI coding
was poor prior to 2010 [39]. Second, we repeated the main analysis but matched bereaved indi-
viduals to non-bereaved individuals using matching without replacement. We performed this
analysis to explore the impact of not accounting for the repeated use of unexposed individuals
across (but not within) matched sets in the main analysis.
Data management and analyses were performed using Stata version 16 (StataCorp, Texas)
in England, and SAS version 9.4 (Cary, NC, USA) in Denmark.
Patient involvement statement
This study was designed and conducted without patient involvement. A bereaved patient rep-
resentative (SL) critically reviewed and interpreted the results, and contributed to the writing
and editing of the manuscript.
Ethics
In England, the study was approved by the London School of Hygiene and Tropical Medicine
Research Ethics Committee (Reference: 16545) and by the CPRD Independent Scientific Advi-
sory Committee (ISAC Protocol Number: 19_034). We did not obtain informed consent since
these data are de-identified. GPs opt-in to sharing de-identified patient data and individual
patients can opt-out. In Denmark, the study was reported to the Danish Data Protection
Agency through registration at Aarhus University (record number 2016-051-000001/812).
Danish legislation does not require approval by an ethical review board or informed consent
from patients for registry-based studies.
Results
Baseline characteristics
In England, we identified 19,820 bereaved people with reduced kidney function and matched
them with 134,828 non-bereaved people with reduced kidney function. In the Danish popula-
tion of bereaved people, we identified 5,408 bereaved people with hospital-diagnosed CKD
and matched them to 35,741 non-bereaved comparisons with CKD (Fig 1).
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We observed equal distribution of sex and age between exposure groups in both cohorts
since we matched on these variables; however, the median age and proportion of females were
higher in England than Denmark (Table 1). Most participants in England had eGFR corre-
sponding to CKD stage 3a and CKD stages were equally distributed in bereaved and non-
bereaved people. Duration of CKD at index date in the Danish cohort was slightly lower in
bereaved than in non-bereaved. Hypertension, ischaemic heart disease, non-haematological
malignancy, and diabetes were the most common comorbidities (Table 1), and comorbidity
prevalence was well balanced between bereaved and non-bereaved groups in both countries.
In England, there was a slightly higher proportion of current smokers in the bereaved
(14.6%) versus non-bereaved group (12.3%), and a slightly lower proportion of current drink-
ers in the bereaved (68.8%) versus non-bereaved group (72.6%). However, the prevalence of
smoking- and alcohol-related comorbidities, such as peptic ulcer and cardiovascular disorders,
was similar in bereaved and non-bereaved in both countries. In England, most participants
were overweight or obese (62.8% of bereaved, 66.1% of non-bereaved people). The bereaved
group had a higher proportion of people in the most deprived IMD quintile (13.9% of
bereaved vs. 11.4% of non-bereaved) although both groups had over-representation of people
in the least deprived quintiles. In Denmark, education level was slightly lower in bereaved than
non-bereaved people (Table 1).
Cardiovascular outcome
In bereaved people, we observed CVD hospitalization rates of CVD of 31.7 per 1,000 person-
years (95%-CI: 30.5–32.9) in England, and of 78.8 per 1,000 person-years (95%-CI: 74.9–82.9)
in Denmark. Compared with non-bereaved people with reduced kidney function, the adjusted
HR of CVD in bereaved was 1.06 (95%-CI: 1.01–1.12) in England and 1.10 (95%-CI: 1.04–
1.17) in Denmark. In both countries, the rate of heart failure was higher than the rate of myo-
cardial infarction and stroke. In England, only heart failure was associated with partner
Fig 1. Flow diagram of cohort sampling in England (1a) and Denmark (1b).
https://doi.org/10.1371/journal.pone.0257255.g001
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Table 1. Baseline characteristics of people with CKD who were bereaved and their non-bereaved matched comparisons in England (1998–2018) and Denmark
(1997–2016).
England Denmark
Bereaved Comparison Bereaved Comparison
Overall, n (%) 19,820 134,828 N = 5,408 N = 35,741
Sex, n (%)
Male 6,809 (34.4) 46,469 (34.5) 2,498 (46.2) 17,411 (48.7)
Female 13,011 (65.6) 88,359 (65.5) 2,910 (53.8) 18,330 (51.3)
Age in years at index date1, median (IQR) 80 (75;84) 81 (76;85) 75.4 (68.5;81.3) 76.3 (69.8;81.7)
Age groups in years at index date1
<65 525 (2.6) 2,803 (2.1) 882 (16.3) 4,439 (12.4)
65–74 3,846 (19.4) 28,883 (21.4) 1,723 (31.9) 11,322 (31.7)
75+ 15,449 (77.9) 103,142 (76.5) 2,803 (51.8) 19,980 (55.9)
Years since CKD diagnosis, median (IQR) NA NA 4.5 (1.8;9.9) 4.4 (1.7;10.0)
CKD stage (based on last recorded eGFR before index date1)
Stage 3a 13,648 (68.9) 95,989 (71.2) NA NA
Stage 3b 4,967 (25.1) 31,910 (23.7) NA NA
Stage 4 1,048 (5.3) 6,031 (4.5) NA NA
Stage 5 157 (0.8) 898 (0.7) NA NA
Hospital-diagnosed acute kidney injury prior to index date1, n (%) 740 (3.7) 3,830 (2.8) 370 (6.8) 2,452 (6.9)
Any Renal replacement therapy (RRT), n (%) 76 (0.4) 602 (0.4) 679 (12.6) 4,342 (12.1)
Type of RRT, n (%)
Kidney transplant NA NA 60 (1.1) 420 (1.2)
Acute dialysis NA NA 290 (5.4) 1,828 (5.1)
Chronic dialysis NA NA 329 (6.1) 2,094 (5.9)
None 19,744 (99.6) 134,226 (99.6) 4,729 (87.4) 31,399 (87.9)
Hospital-diagnosed comorbidity2, n (%)
Myocardial infarction 2,307 (11.6) 14,945 (11.1) 889 (16.4) 5,829 (16.3)
Congestive heart failure 2,852 (14.4) 17,522 (13.0) 1,088 (20.1) 7,163 (20.0)
Peripheral vascular disease 1,618 (8.2) 10,139 (7.5) 1,033 (19.1) 6,811 (19.1)
Cerebrovascular disease 3,114 (15.7) 21,053 (15.6) 1,132 (20.9) 7,961 (22.3)
Dementia 714 (3.6) 4,665 (3.5) 169 (3.1) 1,245 (3.5)
Chronic pulmonary disease 2,108 (10.6) 12,801 (9.5) 915 (16.9) 5,922 (16.6)
Connective tissue disease 1,852 (9.3) 11,900 (8.8) 476 (8.8) 3,450 (9.7)
Peptic ulcer disease 1,838 (9.3) 12,050 (8.9) 641 (11.9) 3,975 (11.1)
Liver disease 198 (1.0) 1,296 (1.0) 161 (3.0) 953 (2.7)
Diabetes 4,432 (22.4) 27,896 (20.7) 1,976 (36.5) 12,473 (34.9)
Non-haematological malignancy 4,500 (22.7) 30,225 (22.4) 1,123 (20.8) 7,882 (22.1)
Haematological malignancy 280 (1.4) 1,931 (1.4) 110 (2.0) 892 (2.5)
Hypertension 14,565 (73.5) 98,876 (73.3) 3,134 (58.0) 21,136 (59.1)
Ischaemic heart disease 6,032 (30.4) 40,125 (29.8) 1,851 (34.2) 12,461 (34.9)
Smoking status, n (%)
Non-smoker 6,012 (30.3) 41,755 (31.0) NA NA
Ex-smoker 10,914 (55.1) 76,543 (56.8)
Current smoker 2,894 (14.6) 16,530 (12.3) NA NA
Alcohol intake, n (%)
Non-drinker 2,509 (12.7) 14,296 (10.6) NA NA
Ex-drinker 3,665 (18.5) 22,642 (16.8) NA NA
Current drinker 13,646 (68.8) 97,890 (72.6) NA NA
(Continued)
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bereavement (HR of 1.08 [95%-CI: 1.00–1.17]), whereas heart failure, myocardial infarction,
and stroke were associated with bereavement in Denmark (Table 2). The increased HR of
CVD associated with bereavement was observed in both sexes in Denmark, while it was
observed in men only in England (Fig 2 and S1 Table). Furthermore, the increased CVD rela-
tive risk in bereaved people was greatest in younger age groups (Fig 2 and S1 Table). When
stratifying by CKD stage in England, there was evidence of greater risk of CVD in bereaved vs.
non-bereaved people with stage 3a (HR 1.10 [95%-CI: 1.03–1.17), while there was no evidence
of an increased risk in those with stage 3b or stages 4–5 (Fig 2 and S1 Table).
AKI outcome
Rates of hospital-recorded AKI in the bereaved groups with reduced kidney function were
comparable in England and Denmark (13.2 per 1,000 person-years [95%-CI: 12.5–14.0] in
England, 11.2 per 1,000 person-years [95%-CI: 9.9–12.7] in Denmark). Compared with non-
bereaved people, bereaved people had a higher risk of AKI with adjusted HRs of 1.20 (95%-CI:
1.10–1.31) in England and 1.36 (95%-CI: 1.17–1.58) in Denmark (Table 2). There were no
clear differences in HRs of AKI between subgroups of age and sex in either setting. In England,
there was no evidence of an increased risk of AKI in bereaved vs. non-bereaved people for
those with CKD stages 4–5. Subgroups with eGFR 45–59 and 30-44mL/min/1.73m2 had simi-
lar increased risks of AKI in the bereaved compared with the non-bereaved groups (HR 1.22
[95%-CI: 1.10–1.36] and HR 1.20 [95%-CI: 1.04–1.38], respectively) (Fig 2 and S1 Table).
Mortality outcome
The mortality rate in bereaved persons with reduced kidney function in England (70.2 per
1,000 person-years [95%-CI: 68.5–72.0]), was lower than that in bereaved CKD patients in
Table 1. (Continued)
England Denmark
Bereaved Comparison Bereaved Comparison
Body mass index (kg m-2), n (%)
Underweight (<18.5) 472 (2.4) 2,291 (1.7) NA NA
Normal weight (18.5–24.9) 6,897 (34.8) 43,381 (32.2) NA NA
Overweight (25–29.9) 7,625 (38.5) 54,907 (40.7) NA NA
Obese (�30) 4,826 (24.3) 34,249 (25.4) NA NA
Index of multiple deprivation, n (%)
1 (least deprived) 4,512 (22.8) 33,964 (25.2) NA NA
2 4,629 (23.4) 34,100 (25.3) NA NA
3 4,375 (22.1) 29,261 (21.7) NA NA
4 3,548 (17.9) 22,117 (16.4) NA NA
5 (most deprived) 2,756 (13.9) 15,386 (11.4) NA NA
Educational attainment (years), n (%)
Short (7–10) NA NA 2,994 (55.4) 17,571 (49.2)
Medium (11–12) NA NA 1,816 (33.6) 13,069 (36.6)
Long (�13) NA NA 598 (11.1) 5,101 (14.3)
1Index date is the bereavement date for the bereaved individual. This same date is the index date for all non-bereaved people within the matched set.
2Comorbidities identified using ICD-10 codes in hospital data (England and Denmark) recorded any time prior to the index date. Read codes recorded by the GP
anytime prior to the index date were also used in England.
CKD: Chronic kidney disease, eGFR: Estimated glomerular filtration, IQR: Interquartile range.
https://doi.org/10.1371/journal.pone.0257255.t001
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Denmark (126.4 per 1,000 person-years [95%-CI: 121.8–131.1]). However, the risk of death
was increased in the bereaved compared with the non-bereaved in both countries (HR 1.10
[95%-CI: 1.05–1.14] in England; HR 1.20 [95%-CI: 1.15–1.25] in Denmark). We found no sub-
stantial differences in HRs of death stratified by subgroups of age or sex. In England, there was
no evidence of an increased risk of death in bereaved compared with non-bereaved people
with CKD stages 4–5 (HR 1.00 [95%-CI: 0.88–1.13]). Subgroups with CKD stages 3a and 3b
had similar increased risks of death in the bereaved compared with the non-bereaved groups
(HR 1.12 [95%-CI: 1.07–1.16] and HR 1.09 [95%-CI: 1.02–1.16], respectively) (Fig 2 and S1
Table).
Sensitivity analyses
We found no substantial changes in our results when restricting to years 2010–2018 or when
sampling matched comparators without replacement in England (S2 and S3 Tables). Hazard
ratios were greatest in the first year of follow-up, and diminished with increasing periods of
follow-up (S4–S6 Tables).
Table 2. Risk of CVD, AKI, and death in person with CKD with or without bereavement in two different populations.


















2621 82747 31.7 (30.5–32.9) 14942 538165 27.8 (27.3–28.2) 1.06 (1.01–1.11) 1.06 (1.01–
1.12)




695 85943 8.09 (7.51–8.71) 4012 556262 7.21 (6.99–7.44) 1.07 (0.98–1.17) 1.03 (0.94–
1.13)
Stroke 846 85993 9.84 (9.20–10.5) 5027 556491 9.03 (8.79–9.29) 0.99 (0.92–1.08) 1.01 (0.93–
1.10)
AKI 1136 85950 13.2 (12.5–14.0) 5560 557977 9.96 (9.71–10.2) 1.18 (1.10–1.27) 1.20 (1.10–
1.31)




1494 18962 78.8 (74.9–82.9) 8265 110315 74.9 (73.3–76.6) 1.12 (1.06–1.18) 1.10 (1.04–
1.17)




414 21333 19.4 (17.6–21.3) 2213 122166 18.1 (17.4–18.9) 1.11 (1.00–1.23) 1.06 (0.94–
1.19)
Stroke 558 20989 26.6 (24.4–28.9) 2811 120888 23.3 (22.4–24.1) 1.17 (1.07–1.28) 1.15 (1.04–
1.27)
AKI 246 21925 11.2 (9.9–12.7) 1157 125022 9.3 (8.7–9.8) 1.40 (1.21–1.62) 1.36 (1.17–
1.58)
Death 2809 22229 126.4 (121.8–
131.1)
13956 126523 110.3 (108.5–
112.1)
1.20 (1.15–1.25) 1.20 (1.15–
1.25)
�England: adjusted for comorbidities (CKD stage, cerebrovascular disease, heart failure, chronic obstructive pulmonary disease, diabetes, hypertension, ischaemic heart
disease, myocardial infarction, peripheral artery disease, connective tissue disease, dementia, peptic ulcers, non-haematological cancer, haematological cancer, liver
disease), history of AKI, smoking status, alcohol consumption, BMI category, IMD category.
�Denmark: adjusted for comorbidities (cerebrovascular disease, heart failure, chronic obstructive pulmonary disease, diabetes, hypertension, ischaemic heart disease,
myocardial infarction, peripheral artery disease, connective tissue disease, dementia, peptic ulcers, non-haematological cancer, haematological cancer, liver disease),
history of AKI, and educational attainment.
AKI: Acute kidney injury, CVD: Cardiovascular disease, CI: Confidence interval, HR: Hazard ratio.
https://doi.org/10.1371/journal.pone.0257255.t002
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Discussion
In people with reduced kidney function, partner bereavement was associated with an increased
risk of CVD hospitalization, AKI hospitalization, and death in both England and Denmark.
The absolute risk of CVD and death was higher in Danish bereaved patients with hospital-
diagnosed CKD compared with English bereaved patients with reduced kidney function in
primary care. We observed slightly higher relative risk estimates for all outcomes in Denmark
compared to England.
Our aim was to explore the hypothesis that partner bereavement in people with reduced
kidney function increased the risk of adverse CVD and kidney-related events, and death. This
question is of particular importance in the context of the COVID-19 pandemic; elderly people
already at increased risk of living with reduced kidney function [1] are likely to be at higher
risk of experiencing partner bereavement due to the pandemic, since COVID-19 mortality
increases with age [40]. Furthermore, pandemic-related stressors such as the recommendation
to shield by the UK government for people with CKD stage 5, and dialysis or transplant recipi-
ents make it more difficult to deal with the practicalities of the death of a partner, and may
lead to worse outcomes. Quantifying the increased risk of adverse events, including death,
associated with this likely increasingly prevalent exposure may encourage healthcare providers
to consider the impact of partner bereavement on high-risk populations during and after the
pandemic.
This is the first study to our knowledge to investigate the effect of partner bereavement on
adverse outcomes specifically in people with reduced kidney function. We showed consistent
results in two countries which strengthens the internal validity of our study. For example,
Fig 2. Forest plot showing adjusted HRs of CVD, AKI and death in bereaved persons with CKD compared to non-bereaved persons with
CKD by sex, age-group, CKD stage (England only).
https://doi.org/10.1371/journal.pone.0257255.g002
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residual confounding by baseline smoking status, alcohol intake, and BMI are unlikely to
account for the observed associations in Denmark since adjusting for these variables in
England did not account for the observed associations in this setting. By triangulating data
within and between two countries using routinely collected healthcare datasets, we were able
to study clinically important outcomes associated with partner bereavement in people with
reduced kidney function. We did not meta-analyse these results since the study populations
were clinically heterogeneous, as patients identified by hospital-diagnosed CKD (Danish
cohort) were younger and had more comorbidities than those with one eGFR measure
<60mL/min/1.73m2 measured in primary care (English cohort) [3].
Our study has some limitations. Residual confounding is possible in both settings due to
imperfect measurement of covariates as well as unmeasured confounders like social network
or diet. Unmeasured confounding by these lifestyle risk factors may partly explain the more
pronounced adjusted HRs in Denmark, yet we did adjust for alcohol- and smoking-related dis-
eases and educational attainment to minimise such confounding.
We may have missed couples in England since we relied on a less sensitive algorithm to
identify partners compared to Denmark. However, because we used the same methods for
identifying bereaved and non-bereaved groups, we do not believe this would have affected our
measures of association. In addition, when restricting to people with available information on
highest educational attainment in Denmark, we primarily excluded people born before 1945
as the educational registries are virtually complete for people born after 1945 [32].
We did not exclude people with histories of CVD or AKI, meaning it is possible these prev-
alent conditions were recorded as secondary diagnoses which we incorrectly classified as inci-
dent outcome events. Moreover, we did not include outpatient hospital data and
cardiovascular and renal disease audit data in England, such as the Myocardial Ischaemia
National Audit Project (MINAP) and the UK Renal Registry (UKRR). Thus, we likely missed
CVD and AKI outcomes in England. In particular, detection of myocardial infarction hospital-
ization has been shown to be improved by combining MINAP and HES data [41]. Excluding
these data likely underestimated the incidence of study outcomes and diluted effect estimates
in England, and might partly explain why incidence of outcomes were higher in Denmark.
Bereaved people without a caregiver at home may be more likely to present to hospital for
heart failure, which may partly explain the increased risk in bereaved vs. non-bereaved people.
However, this surveillance bias would not explain the increased relative risk of death in
bereaved vs. non-bereaved people.
In England, we found no association between bereavement and outcomes of interest in peo-
ple with CKD stages 4–5 (eGFR 0-30mL/min/1.73m2). In contrast, we found more pro-
nounced relative risks for all study outcomes in Denmark, where patients were identified
through hospital records and thus likely had more advanced CKD on average. However, as we
were unable to stratify by eGFR levels, we do not know if stage modified the associations of
interest in Denmark as well. It is possible that additional supportive care for people with
advanced CKD received in nephrology clinics reduces the relative risk of adverse events after
partner bereavement and accounts for the null association in this group. Furthermore, people
with advanced kidney disease are generally older and multimorbid and may not experience as
significant a change in disease status due to acute stressors like bereavement compared to peo-
ple with less advanced kidney disease. This may explain why we observed a concentration of
the increased risk of adverse outcomes post-partner bereavement in people with less advanced
kidney dysfunction in England.
Finally, in our main analysis, we sampled our unexposed groups with replacement. This
technique may have resulted in too narrow confidence intervals due to the inclusion of some
persons in multiple strata, thus leading to artificial statistical homogeneity. However, our
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sensitivity analysis in England showed no change in the interpretation of our results when we
re-sampled the comparison cohort without replacement.
Previous studies have shown an increased risk of CVD and mortality in people who experi-
enced partner bereavement compared with those with a living partner [12,13], particularly in
the short-term [21]. Our study of people with reduced kidney function thus supports these
previous findings overall. Unlike previous studies, the association with CVD was driven by an
increased risk of heart failure rather than myocardial infarction. This finding could be
explained by poor adherence to medications, in particular diuretics, in people with reduced
kidney function after the death of their partner, which in turn could cause fluid retention and
ultimately heart failure. Further research is needed to understand possible mechanisms to
explain the adverse events associated with bereavement in people with reduced kidney func-
tion and the possible benefits of interventions for closer monitoring and support.
In conclusion, we found an increased risk of CVD and AKI hospitalizations, and death in
people with reduced kidney function who experience partner bereavement compared with
people with a living partner. Further observational research to investigate possible mechanisms
of this association, for example poor adherence to prescriptions in bereaved individuals,
stress-induced pathophysiology, and loneliness, could identify targets to reduce adverse events
in this vulnerable population.
Supporting information
S1 Table. Association between partner bereavement and study outcomes stratified by age
group, sex, and CKD stage.
(DOCX)
S2 Table. Risk of CVD, AKI, and death in persons with CKD with or without bereavement
restricting study period to 2010–2018 (England only).
(DOCX)
S3 Table. Sensitivity analysis–repeat main analysis in English cohort using matching with-
out replacement.
(DOCX)
S4 Table. Risk of CVD in person with CKD with or without bereavement in England and
Denmark stratified by follow-up periods.
(DOCX)
S5 Table. Risk of AKI in person with CKD with or without bereavement in England and
Denmark stratified by follow-up periods.
(DOCX)
S6 Table. Risk of death in person with CKD with or without bereavement in England and
Denmark stratified by follow-up periods.
(DOCX)
S1 Methods. Data sources–England.
(DOCX)
S2 Methods. Data sources–Denmark.
(DOCX)
S3 Methods. Partner identification–England.
(DOCX)
PLOS ONE Adverse outcomes after partner bereavement in people with reduced kidney function
PLOS ONE | https://doi.org/10.1371/journal.pone.0257255 September 23, 2021 12 / 15
S4 Methods. Partner identification–Denmark.
(DOCX)
S5 Methods. Lifestyle risk factor algorithms–England.
(DOCX)
S6 Methods. Comorbidity codelists (ICD-8 or ICD-10)–Denmark.
(DOCX)
S7 Methods. Renal Replacement Therapy (RRT) codelist–Denmark.
(DOCX)
Acknowledgments
This study is based in part on data from the Clinical Practice Research Datalink obtained
under licence from the UK Medicines and Healthcare products Regulatory Agency. The data
are provided by patients and collected by the NHS as part of their care and support. The inter-
pretation and conclusions contained in this study are those of the authors alone.
Author Contributions
Conceptualization: Dorothea Nitsch.
Data curation: Patrick Bidulka, Søren Viborg Vestergaard, Anders Kjærsgaard, Angel Y. S.
Wong, Sigrun Alba Johannesdottir Schmidt, Dorothea Nitsch.
Formal analysis: Patrick Bidulka, Søren Viborg Vestergaard, Admire Hlupeni, Anders
Kjærsgaard.
Funding acquisition: Sinéad M. Langan.
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